Effect of Circadian Rhythm on the Sedative Efficacy and Recovery Quality of Ciprofol General Anesthesia: A Multi-Center Observational Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Surgery commences in the morning., Surgery commences in the afternoon..
- Who it may be relevant to
- Registry conditions: Circadian Rhythm, Ciprofol, Hemodynamic Instability, Anesthetics Adverse Reaction. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The goal of this multi-center observational study is to learn about the effect of circadian rhythm (morning vs. afternoon surgery) on the sedative efficacy, hemodynamic stability (especially induction-associated hypotension), and recovery quality of ciprofol general anesthesia in adult patients undergoing elective non-cardiac and non-cranial surgery, comparing target-controlled infusion (TCI) and non-TCI administration modes. The main question it aims to answer is: Does circadian rhythm (time of surgery: morning vs. afternoon) affect the sedative efficacy, incidence of induction-associated hypotension, and recovery quality of ciprofol general anesthesia? Eligible patients aged 18-65 years with ASA physical status I-II and BMI 18-30 kg/m² undergoing elective general anesthesia for non-cardiac and non-cranial surgery (duration 1-2 hours) will be grouped by anesthesia start time (morning: 08:00-11:00; afternoon: 14:00-17:00) and receive ciprofol induction and maintenance via TCI or non-TCI infusion. Perioperative data including hemodynamic changes, ciprofol dosage, recovery time, and adverse events will be recorded and analyzed.
Interventions
- Other Surgery commences in the morning.
The morning group was defined as patients whose surgery commenced between 08:00 and 11:00 and concluded by 13:00. - Other Surgery commences in the afternoon.
The afternoon group was defined as patients whose surgery commenced between 14:00 and 17:00 and concluded by 19:00.
Primary outcome measures
- Incidence of hypotension during the induction period [Time frame: From the time of initial anesthetic drug administration until 5 minutes after completion of tracheal intubation (maximum duration limited to 20 minutes)]
Secondary outcome measures (10)
- Incidence of mean arterial pressure decreasing by >30% from baseline during the induction period and lasting for ≥1 minute. [Time frame: From the time of initial anesthetic drug administration until 5 minutes after completion of tracheal intubation (maximum duration limited to 20 minutes)]
- Incidence of MAP staying below 65 mmHg for at least 1 minute during the anesthetic maintenance [Time frame: From 5 minutes after completion of tracheal intubation until the time of discontinuation of all anesthetic agents at the end of surgery, assessed up to 24 hours.]
- Incidence of MAP reduction > 20% from baseline during the anesthetic maintenance period [Time frame: From 5 minutes after completion of tracheal intubation until the time of discontinuation of all anesthetic agents at the end of surgery, assessed up to 24 hours.]
- Incidence of MAP reduction > 30% from baseline during the anesthetic maintenance period [Time frame: From 5 minutes after completion of tracheal intubation until the time of discontinuation of all anesthetic agents at the end of surgery, assessed up to 24 hours.]
- Total administered dose of vasoactive agents [Time frame: From the time of initial anesthetic drug administration until the time of discontinuation of anesthetic infusion at the end of surgery,assessed up to 24 hours.]
- Incidence of hypertension throughout anesthesia [Time frame: From the time of initial anesthetic drug administration until the time of discontinuation of anesthetic infusion at the end of surgery,assessed up to 24 hours.]
- Time to successful anesthetic induction [Time frame: From the time of initial anesthetic drug administration until the time of disappearance of the patient's eyelash reflex, assessed up to 20 minutes.]
- Time to emergence [Time frame: From the time of discontinuation of anesthetic infusion until the time of the patient's first eye opening, assessed up to 2 hours.]
- Time to extubation [Time frame: From the time of discontinuation of anesthetic infusion until the time of tracheal tube removal, assessed up to 2 hours.]
- Bispectral Index [Time frame: From the patient's awake state before anesthetic induction until the time when the patient emerges from anesthesia and leaves the operating room for the ward after surgery, assessed up to 24 hours.]
Eligibility criteria
Inclusion criteria
- Aged 18-65 years, with ASA physical status I-II.
- Body Mass Index (BMI) between 18-30 kg/m².
- Scheduled for elective non-cardiac and non-intracranial surgery under general anesthesia, with an expected operative duration of 1-2 hours.
- Morning group: surgery start time between 08:00 and 11:00, with completion no later than 13:00; Afternoon group: surgery start time between 14:00 and 17:00, with completion no later than 19:00.
- Willing to participate and having provided signed informed consent.
Exclusion criteria
- Severe hepatic or renal insufficiency (Child-Pugh Class C or eGFR < 30 ml/min/1.73m²).
- Severe cardiovascular, respiratory, or neurological diseases.
- Long-term use of sedative-hypnotics, anxiolytics, antidepressants, or glucocorticoids.
- Known allergy to ciprofol, propofol, or their excipients.
- Recent (within 3 months) history of shift work, transmeridian travel, or other conditions that may cause circadian rhythm disruption.
- Pregnant or lactating women.
- Any other condition deemed by the investigator as unsuitable for participation in this study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07686432 · 2026EC083